X0306 4 2018-05-17 0001099800 Edwards Lifesciences Corp EW 0001204551 MUSSALLEM MICHAEL A ONE EDWARDS WAY IRVINE CA 92614 1 1 Chairman & CEO Common Stock 2018-05-17 4 M 0 32900.0000 42.7250 A 112730.8200 D Common Stock 2018-05-17 4 A 0 10600.0000 0.0000 A 123330.8200 D Common Stock 2018-05-17 4 S 0 5800.0000 136.3991 D 117530.8200 D Common Stock 2018-05-17 4 S 0 27100.0000 135.7698 D 90430.8200 D Common Stock 123931.0030 I 401(k) Common Stock 698095.0000 I By Living Trust Employee Stock Option (Right to Acquire) 42.7250 2018-05-17 4 M 0 32900.0000 0.0000 D 2012-06-09 2019-05-08 Common Stock 32900.0000 286900.0000 D Employee Stock Option (Right to Acquire) 135.8300 2018-05-17 4 A 0 104300.0000 0.0000 A 2018-06-17 2025-05-16 Common Stock 104300.0000 104300.0000 D Performance Rights 2018-05-17 4 A 0 13250.0000 0.0000 A 2021-05-17 2025-05-16 Common Stock 13250.0000 13250.0000 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018. These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. This transaction was executed in multiple trades at prices ranging from $136.23 to $136.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $135.23 to $136.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Shares represented on the most recent statement of the 401(k) Plan Administrator where a unitized accounting procedure is utilized to convert the equities to share equivalents. These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Linda J. Park, Attorney-in-Fact 2018-05-21